KANK1 sirna

KANK1 siRNA (Human)

Cat. Num. AAA8233289

• Gene Names: KANK1; KANK; CPSQ2; ANKRD15
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: KANK1; KANK1 siRNA (Human); ANKRD15; KANK; KIAA0172; KN motif and ankyrin repeat domain-containing protein 1; Ankyrin repeat domain-containing protein 15; Kidney ankyrin repeat-containing protein; KANK1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: KANK1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1352

• Applicable Applications for KANK1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human KANK1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for KANK1 sirna

siRNA to inhibit KANK1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 379056374
• NCBI GeneID: 23189
• NCBI Accession #: NP_001243805.1
• NCBI GenBank Nucleotide #: NM_001256876.1
• UniProt Accession #: Q14678; Q5W0W0; Q8IY65; Q8WX74; A2A2W8; D3DRH3
• Molecular Weight: 129,782 Da
• NCBI Official Full Name: KN motif and ankyrin repeat domain-containing protein 1 isoform a
• NCBI Official Synonym Full Names: KN motif and ankyrin repeat domains 1
• NCBI Official Symbol: KANK1
• NCBI Official Synonym Symbols: KANK; CPSQ2; ANKRD15
• NCBI Protein Information: KN motif and ankyrin repeat domain-containing protein 1
• UniProt Protein Name: KN motif and ankyrin repeat domain-containing protein 1
• Protein Family: KN motif and ankyrin repeat domain-containing protein
• UniProt Gene Name: KANK1
• UniProt Synonym Gene Names: ANKRD15; KANK; KIAA0172
• UniProt Entry Name: KANK1_HUMAN

NCBI Description

The protein encoded by this gene belongs to the Kank family of proteins, which contain multiple ankyrin repeat domains. This family member functions in cytoskeleton formation by regulating actin polymerization. This gene is a candidate tumor suppressor for renal cell carcinoma. Mutations in this gene cause cerebral palsy spastic quadriplegic type 2, a central nervous system development disorder. A t(5;9) translocation results in fusion of the platelet-derived growth factor receptor beta gene (PDGFRB) on chromosome 5 with this gene in a myeloproliferative neoplasm featuring severe thrombocythemia. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome 20. [provided by RefSeq, Dec 2014]

Uniprot Description

ANKRD15: Involved in the control of cytoskeleton formation by regulating actin polymerization. Inhibits actin fiber formation and cell migration. Inhibits RhoA activity; the function involves phosphorylation through PI3K/Akt signaling and may depend on the competetive interaction with 14-3-3 adapter proteins to sequester them from active complexes. Inhibits the formation of lamellipodia but not of filopodia; the function may depend on the competetive interaction with BAIAP2 to block its association with activated RAC1. Inhibits fibronectin-mediated cell spreading; the function is partially mediated by BAIAP2. Inhibits neurite outgrowth. Involved in the establishment and persistence of cell polarity during directed cell movement in wound healing. In the nucleus, is involved in beta-catenin-dependent activation of transcription. Potential tumor suppressor for renal cell carcinoma. Defects in KANK1 are the cause of cerebral palsy spastic quadriplegic type 2 (CPSQ2). A non-progressive disorder of movement and/or posture resulting from defects in the developing central nervous system. Affected individuals manifest congenital hypotonia evolving over the first year to spastic quadriplegia with accompanying transient nystagmus and varying degrees of mental retardation. Neuroimaging shows brain atrophy and ventriculomegaly. 2 isoforms of the human protein are produced by alternative promoter.

Protein type: Tumor suppressor

Chromosomal Location of Human Ortholog: 9p24.3

Cellular Component: cytoplasm; nucleus

Molecular Function: protein binding; beta-catenin binding

Biological Process: negative regulation of Rho protein signal transduction; transcription, DNA-dependent; regulation of transcription, DNA-dependent; negative regulation of actin filament polymerization; negative regulation of insulin receptor signaling pathway; positive regulation of Wnt receptor signaling pathway; negative regulation of cell migration

Disease: Cerebral Palsy, Spastic Quadriplegic, 2